Legato Capital Management’s Vita Coco COCO Stock Holding History

Legato Capital Management’s Portfolio COCO Stock Details COCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9,840	Closed	-$256K	–	583
2023 Q3	$256K	Sell	9,840 -9,905	-50%	-$264K	0.04%	496
2023 Q2	$531K	Buy	+19,745	New	+$481K	0.07%	410

Other funds holding COCO

Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Legato Capital Management's COCO Position: Q4 2023 in Review

Legato Capital Management sold out of Vita Coco (COCO) in Q4 2023, closing a stake of 9,840 shares — an estimated $256K sold.

Legato Capital Management first reported a position in COCO in Q2 2023 and held it in 2 quarters. The position peaked at $531K in Q2 2023. 181 funds tracked by Wall St. Rank hold COCO as of Q4 2023.

Legato Capital Management reported no remaining Vita Coco position as of Q4 2023 after selling out during the quarter.
Legato Capital Management sold 9,840 Vita Coco shares in Q4 2023, an estimated $256K.
Legato Capital Management first reported a position in Vita Coco in Q2 2023 and held it in 2 quarters.
Legato Capital Management's Vita Coco position peaked at $531K in Q2 2023.
181 funds tracked by Wall St. Rank held Vita Coco as of Q4 2023.

Based on Legato Capital Management's 13F filing for Q4 2023, filed 16 Jan 2024.